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The focus of cardiovascular disease prevention has shifted from normalisation of risk factors to absolute 15 
risk reduction. Reducing low-density lipoprotein cholesterol (LDL-C) concentration by 1 mmol/L for 16 
around 5 years is consistently associated with a 23-25% lower risk of major cardiovascular events, for 17 
statin and non-statin therapies alike, regardless of the baseline LDL-C level.1 In high and middle income 18 
countries, statins are now routinely recommended as first line LDL-C-lowering therapy for people with 19 
10 year modelled risk above somewhat arbitrary, country-specific thresholds defined by economic and 20 
clinical considerations. This high-risk category includes most patients with type 2 diabetes. Statins 21 
achieve similar reductions in relative risk among people with and without diabetes.2 However, even 22 
among patients on maximum doses, with LDL-C levels in the normal range, further reductions in LDL-23 
C and modelled risk are possible. 24 
 25 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme catalyses the degradation of the LDL 26 
receptor, thereby reducing LDL-C uptake by cells and increasing circulating levels. In this issue, 27 
Sabatine and colleagues report the efficacy and safety of PCSK9 inhibition in people with and without 28 
diabetes.3 They undertook a pre-specified secondary analysis of data from FOURIER, a randomised 29 
controlled trial of subcutaneous injections of the monoclonal antibody Evolocumab or placebo every 2 30 
or 4 weeks, in 27,564 patients with atherosclerotic disease and prescribed statin therapy. The effect of 31 
Evolocumab on LDL-C concentration (~1.5 mmol/L reduction at 48 weeks) and risk of the composite 32 
cardiovascular endpoint over 2.2 years (hazard ratio 0.83; 95%CI:0.75 to 0.93) was similar in 33 
participants with diabetes compared to those without. Consideration of adverse effects is particularly 34 
important given the historical controversy over statins. Evolucumab was well tolerated. The frequency 35 
of adverse effects (for example muscle-related and neurocognitive) was similar in the two study arms, 36 
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as was drug discontinuation, which occurred less often (5.7%/year) than in the IMPROVE-IT trial of 37 
the addition of once daily oral Ezetimibe to statin therapy (7%/year).4 38 
 39 
One concern related to statins is the increased risk of type 2 diabetes,5 albeit the net effect on risk of 40 
cardiovascular disease, the most burdensome complication of diabetes, strongly justifies their use. 41 
Meta-analyses of statin trials including over 90,000 patients followed for 4.2 years, and Mendelian 42 
randomisation studies of LDL-C lowering variants near the gene encoding the HMG-coenzyme A 43 
reductase protein (the target for statins) confirm an adverse effect of statins on weight (0.24kg higher) 44 
and incidence of diabetes (12% higher).5 Genetic studies including data from more than half a million 45 
individuals have demonstrated associations between PCSK9 variants and weight (1.03kg higher), 46 
fasting glucose (0.09 mmol/L higher) and odds of diabetes (19 to 29% higher).6,7 The FOURIER 47 
investigators report no evidence of an association between Evolocumab and weight, glycated 48 
haemoglobin and incidence of diabetes (hazard ratio 1.05; 95% CI:0.94 to 1.17). These results reassure 49 
us  that PCSK9 inhibition is unlikely to have a major impact on diabetes risk. FOURIER was adequately 50 
powered to detect effect sizes observed in genetic studies. However, estimates from genetic studies are 51 
scaled to a 1mmol/l lower LDL-C concentration and reflect a life-long exposure to differences in 52 
PCSK9 function in the general population. By contrast, FOURIER investigated pharmacological 53 
PCSK9 inhibition reducing LDL-C by 1.5mmol/l over 2.2 years of follow-up, in the setting of a high-54 
risk population previously exposed to statin treatment. Hence, a small to moderate effect of Evolocumab 55 
on diabetes risk will only be excluded by pooling of data from several trials, as undertaken for statins. 56 
The consistency of results of genetic studies and trials highlights as yet unexplained mechanisms in the 57 
aetiology of diabetes that merit further investigation. The discrepancy in effect sizes between genetic 58 
studies and trials raises the possibility that cardiovascular risk reductions of greater than 25% could be 59 
achieved through longer term treatment from an earlier age. As the rationale for basing prescribing 60 
decisions on absolute risk assumes a consistent effect size, perhaps we should consider incorporating 61 
age-sex standardised rather than absolute risk into guidelines and shared decision-making. 62 
 63 
Ezetimibe is the recommended additional LDL-C lowering therapy for patients prescribed maximum 64 
tolerated dose statin. While considerably cheaper than Evolocumab, it has a smaller effect on LDL-C. 65 
In IMPROVE-IT, adding Ezetimibe to statins achieved a reduction of 0.43 mmol/L in LDL-C compared 66 
to placebo, and was associated with a greater reduction in relative risk of cardiovascular events among 67 
people with diabetes than those without. FOURIER data suggest that Evolucumab is an effective and 68 
safe option for patients with diabetes and atherosclerotic disease. If PCSK9 inhibitors, or other emerging 69 
therapies, have few adverse effects, including minimal impact on diabetes risk, this might influence 70 
prescribing decisions. However, for the vast majority of the half a billion people with type 2 diabetes 71 
worldwide, access to PCSK9 inhibitors is likely to be limited for the forseable future by their cost.8 72 
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